Clinical Trial Update: A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily [Phase 3]

View source ↗

Summary

Phase 3 trial comparing adding once-daily insulin aspart versus switching to a basal-bolus regimen with insulin degludec and insulin aspart in adults with type …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoLog (insulin aspart)
• Tresiba (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-11-13